Genetic insight into sick sinus syndrome. Is there a pill for it or how far are we on the translational road to personalized medicine?
(Source: European Heart Journal)
Source: European Heart Journal - April 16, 2021 Category: Cardiology Source Type: research
Can a single genetic variant explain residual cardiovascular risk by modifying NLRP3 expression?
(Source: European Heart Journal)
Source: European Heart Journal - April 14, 2021 Category: Cardiology Source Type: research
Hitting the right channels to spread a ‘no-restenosis’ message to vascular wall cells
(Source: European Heart Journal)
Source: European Heart Journal - April 14, 2021 Category: Cardiology Source Type: research
The Jessa Hospital experience for cardiac rehabilitation
The ESC and EAPC reference centre for cardiac rehabilitation presents its accelerated programme for cardiac rehabilitation brought about by COVID-19 (Source: European Heart Journal)
Source: European Heart Journal - April 14, 2021 Category: Cardiology Source Type: research
Old and new enemies: psychological stress, occupational stress, COVID-19, and a glimpse of the future
(Source: European Heart Journal)
Source: European Heart Journal - April 14, 2021 Category: Cardiology Source Type: research
A call to action for new global approaches to cardiovascular disease drug solutions
AbstractWhilst we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the in...
Source: European Heart Journal - April 13, 2021 Category: Cardiology Source Type: research
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults
Conclusion Higher leisure time physical activity associates with reduced MACE and all-cause mortality risk, while higher occupational physical activity associates with increased risks, independent of each other. (Source: European Heart Journal)
Source: European Heart Journal - April 9, 2021 Category: Cardiology Source Type: research
Prevention of cardiovascular disease: does ‘every step counts’ apply for occupational work?
(Source: European Heart Journal)
Source: European Heart Journal - April 9, 2021 Category: Cardiology Source Type: research
A proteomic atlas of the neointima identifies novel druggable targets for preventive therapy
Conclusions Our study provides a proteomic atlas of the healthy and injured arterial wall that can be used to define novel factors for therapeutic targeting. We present TRPC6 as an actionable target to prevent neointima formation secondary to vascular injury and stent implantation. (Source: European Heart Journal)
Source: European Heart Journal - April 8, 2021 Category: Cardiology Source Type: research
Erratum to: Conducting Clinical Trials in Heart Failure During (and After) the COVID-19 Pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Erratum to: Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) [Eur Heart J (2020); doi:10.1093/eurheartj/ehaa461]. (Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
AbstractCardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scena...
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research
To stent or not to stent? Treating angina after ISCHEMIA —the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease
The ISCHEMIA trial is a large, multinational trial sponsored by the National Heart, Lung, and Blood Institute, which has recently been published.1 The main trial compares coronary revascularization and optimal medical therapy (OMT) vs. OMT alone in 5179 patients enrolled after stress testing, in addition to two ancillary studies in patients with chronic kidney disease (777 patients)2 and a quality of life sub-study in the main ISCHEMIA trial, which enrolled 4617 patients.3Crucial to placing the results of this important trial into perspective is a review of where we stood prior to the publication of ISCHEMIA, in regard to ...
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research
Dr Raphael Twerenbold
In an EHJ CardioPulse series looking at the next generation of leaders in cardiology, Mark Nicholls speaks to Dr Raphael Twerenbold about his clinical and research focus (Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research
Guidelines on myocardial infarction, novel therapeutic targets in post-infarction remodelling, and a debate on the ISCHEMIA trial
(Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research
Interleukin-1 blockade: a paradigm shift in the treatment of patients with recurrent pericarditis?
Comment on “Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis”, which was presented at the American Heart Association 2020 Scientific Sessions and published in the New England Journal of Medicine (https://doi.org/10.1056/NEJMoa2027892) (Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research
